Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0U2DH
|
|||
Former ID |
DNC003569
|
|||
Drug Name |
CC-1088
|
|||
Synonyms |
CDC801; CC-1088; CHEMBL88153; SCHEMBL185853; CDC-801; DDYUBCCTNHWSQM-UHFFFAOYSA-N; BDBM50216298; HY-U00179; CS-7247; 192819-27-5
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 2 | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C23H24N2O5
|
|||
Canonical SMILES |
COC1=C(C=C(C=C1)C(CC(=O)N)N2C(=O)C3=CC=CC=C3C2=O)OC4CCCC4
|
|||
InChI |
1S/C23H24N2O5/c1-29-19-11-10-14(12-20(19)30-15-6-2-3-7-15)18(13-21(24)26)25-22(27)16-8-4-5-9-17(16)23(25)28/h4-5,8-12,15,18H,2-3,6-7,13H2,1H3,(H2,24,26)
|
|||
InChIKey |
DDYUBCCTNHWSQM-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 192819-27-5
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Phosphodiesterase 4A (PDE4A) | Target Info | Inhibitor | [2] |
Phosphodiesterase 4B (PDE4B) | Target Info | Inhibitor | [2] | |
Phosphodiesterase 4D (PDE4D) | Target Info | Inhibitor | [2] | |
KEGG Pathway | Purine metabolism | |||
cAMP signaling pathway | ||||
Morphine addiction | ||||
NetPath Pathway | IL5 Signaling Pathway | |||
IL2 Signaling Pathway | ||||
Pathwhiz Pathway | Purine Metabolism | |||
Reactome | DARPP-32 events | |||
G alpha (s) signalling events | ||||
WikiPathways | G Protein Signaling Pathways | |||
Myometrial Relaxation and Contraction Pathways | ||||
Nuclear Receptors Meta-Pathway | ||||
Opioid Signalling | ||||
TSH signaling pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT00045786) Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes. U.S. National Institutes of Health. | |||
REF 2 | Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669-74. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.